Management of anemia in chronic kidney disease patients: Baseline findings from Chronic Kidney Disease Japan Cohort Study

Tadao Akizawa, Hirofumi Makino, Seiichi Matsuo, Tsuyoshi Watanabe, Enyu Imai, Kosaku Nitta, Yasuo Ohashi, Akira Hishida

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Anemia is a factor that affects the outcome of patients with chronic kidney disease (CKD); however, there are only a few reports on the management of anemia in Japanese patients with CKD who are not on dialysis. Methods: We investigated the prevalence, related factors and management of anemia in CKD stage 3-5 patients in Japan based on the baseline data obtained from a prospective cohort study (Chronic Kidney Disease Japan Cohort). Anemia was defined as having a hemoglobin (Hb) level of <11 g/dL or receiving erythropoiesis stimulating agent (ESA) therapy. Results: The result indicated that 946 out of 2,930 patients had anemia. Of these 946 patients, 385 were receiving ESA treatment for anemia and had an Hb level of 10.28 ± 1.19 g/dL (mean ± SD). The percentage of these patients with an Hb level above the target of 11 g/dL proposed for treatment by the Japanese guidelines, and above the maintenance level of 10 g/dL approved for ESA therapy in Japan, was only 30.1 and 61.6%, respectively. In contrast, the percentage of patients receiving no ESA therapy was 67.6 and 55.7%, respectively, among those with an Hb level of <11 and <10 g/dL. Conclusions: These data suggested that prevalence of anemia was high in Japanese patients with CKD stage 3-5, that the percentage of patients receiving ESA was low among those who required ESA, and that a large number of patients receiving ESA failed to maintain the recommended level of Hb.

Original languageEnglish
Pages (from-to)248-257
Number of pages10
JournalClinical and Experimental Nephrology
Volume15
Issue number2
DOIs
Publication statusPublished - Apr 1 2011

Fingerprint

Chronic Renal Insufficiency
Hematinics
Anemia
Japan
Cohort Studies
Hemoglobins
Therapeutics
Dialysis
Maintenance
Prospective Studies
Guidelines

Keywords

  • Anemia
  • CKD
  • Erythropoiesis stimulating agent (ESA)
  • Hemoglobin (Hb)

ASJC Scopus subject areas

  • Nephrology
  • Physiology
  • Physiology (medical)

Cite this

Management of anemia in chronic kidney disease patients : Baseline findings from Chronic Kidney Disease Japan Cohort Study. / Akizawa, Tadao; Makino, Hirofumi; Matsuo, Seiichi; Watanabe, Tsuyoshi; Imai, Enyu; Nitta, Kosaku; Ohashi, Yasuo; Hishida, Akira.

In: Clinical and Experimental Nephrology, Vol. 15, No. 2, 01.04.2011, p. 248-257.

Research output: Contribution to journalArticle

Akizawa, Tadao ; Makino, Hirofumi ; Matsuo, Seiichi ; Watanabe, Tsuyoshi ; Imai, Enyu ; Nitta, Kosaku ; Ohashi, Yasuo ; Hishida, Akira. / Management of anemia in chronic kidney disease patients : Baseline findings from Chronic Kidney Disease Japan Cohort Study. In: Clinical and Experimental Nephrology. 2011 ; Vol. 15, No. 2. pp. 248-257.
@article{6fc9db60c02f46f89d20ddc348b03c5a,
title = "Management of anemia in chronic kidney disease patients: Baseline findings from Chronic Kidney Disease Japan Cohort Study",
abstract = "Background: Anemia is a factor that affects the outcome of patients with chronic kidney disease (CKD); however, there are only a few reports on the management of anemia in Japanese patients with CKD who are not on dialysis. Methods: We investigated the prevalence, related factors and management of anemia in CKD stage 3-5 patients in Japan based on the baseline data obtained from a prospective cohort study (Chronic Kidney Disease Japan Cohort). Anemia was defined as having a hemoglobin (Hb) level of <11 g/dL or receiving erythropoiesis stimulating agent (ESA) therapy. Results: The result indicated that 946 out of 2,930 patients had anemia. Of these 946 patients, 385 were receiving ESA treatment for anemia and had an Hb level of 10.28 ± 1.19 g/dL (mean ± SD). The percentage of these patients with an Hb level above the target of 11 g/dL proposed for treatment by the Japanese guidelines, and above the maintenance level of 10 g/dL approved for ESA therapy in Japan, was only 30.1 and 61.6{\%}, respectively. In contrast, the percentage of patients receiving no ESA therapy was 67.6 and 55.7{\%}, respectively, among those with an Hb level of <11 and <10 g/dL. Conclusions: These data suggested that prevalence of anemia was high in Japanese patients with CKD stage 3-5, that the percentage of patients receiving ESA was low among those who required ESA, and that a large number of patients receiving ESA failed to maintain the recommended level of Hb.",
keywords = "Anemia, CKD, Erythropoiesis stimulating agent (ESA), Hemoglobin (Hb)",
author = "Tadao Akizawa and Hirofumi Makino and Seiichi Matsuo and Tsuyoshi Watanabe and Enyu Imai and Kosaku Nitta and Yasuo Ohashi and Akira Hishida",
year = "2011",
month = "4",
day = "1",
doi = "10.1007/s10157-010-0396-7",
language = "English",
volume = "15",
pages = "248--257",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Management of anemia in chronic kidney disease patients

T2 - Baseline findings from Chronic Kidney Disease Japan Cohort Study

AU - Akizawa, Tadao

AU - Makino, Hirofumi

AU - Matsuo, Seiichi

AU - Watanabe, Tsuyoshi

AU - Imai, Enyu

AU - Nitta, Kosaku

AU - Ohashi, Yasuo

AU - Hishida, Akira

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Background: Anemia is a factor that affects the outcome of patients with chronic kidney disease (CKD); however, there are only a few reports on the management of anemia in Japanese patients with CKD who are not on dialysis. Methods: We investigated the prevalence, related factors and management of anemia in CKD stage 3-5 patients in Japan based on the baseline data obtained from a prospective cohort study (Chronic Kidney Disease Japan Cohort). Anemia was defined as having a hemoglobin (Hb) level of <11 g/dL or receiving erythropoiesis stimulating agent (ESA) therapy. Results: The result indicated that 946 out of 2,930 patients had anemia. Of these 946 patients, 385 were receiving ESA treatment for anemia and had an Hb level of 10.28 ± 1.19 g/dL (mean ± SD). The percentage of these patients with an Hb level above the target of 11 g/dL proposed for treatment by the Japanese guidelines, and above the maintenance level of 10 g/dL approved for ESA therapy in Japan, was only 30.1 and 61.6%, respectively. In contrast, the percentage of patients receiving no ESA therapy was 67.6 and 55.7%, respectively, among those with an Hb level of <11 and <10 g/dL. Conclusions: These data suggested that prevalence of anemia was high in Japanese patients with CKD stage 3-5, that the percentage of patients receiving ESA was low among those who required ESA, and that a large number of patients receiving ESA failed to maintain the recommended level of Hb.

AB - Background: Anemia is a factor that affects the outcome of patients with chronic kidney disease (CKD); however, there are only a few reports on the management of anemia in Japanese patients with CKD who are not on dialysis. Methods: We investigated the prevalence, related factors and management of anemia in CKD stage 3-5 patients in Japan based on the baseline data obtained from a prospective cohort study (Chronic Kidney Disease Japan Cohort). Anemia was defined as having a hemoglobin (Hb) level of <11 g/dL or receiving erythropoiesis stimulating agent (ESA) therapy. Results: The result indicated that 946 out of 2,930 patients had anemia. Of these 946 patients, 385 were receiving ESA treatment for anemia and had an Hb level of 10.28 ± 1.19 g/dL (mean ± SD). The percentage of these patients with an Hb level above the target of 11 g/dL proposed for treatment by the Japanese guidelines, and above the maintenance level of 10 g/dL approved for ESA therapy in Japan, was only 30.1 and 61.6%, respectively. In contrast, the percentage of patients receiving no ESA therapy was 67.6 and 55.7%, respectively, among those with an Hb level of <11 and <10 g/dL. Conclusions: These data suggested that prevalence of anemia was high in Japanese patients with CKD stage 3-5, that the percentage of patients receiving ESA was low among those who required ESA, and that a large number of patients receiving ESA failed to maintain the recommended level of Hb.

KW - Anemia

KW - CKD

KW - Erythropoiesis stimulating agent (ESA)

KW - Hemoglobin (Hb)

UR - http://www.scopus.com/inward/record.url?scp=79959233106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959233106&partnerID=8YFLogxK

U2 - 10.1007/s10157-010-0396-7

DO - 10.1007/s10157-010-0396-7

M3 - Article

C2 - 21234785

AN - SCOPUS:79959233106

VL - 15

SP - 248

EP - 257

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 2

ER -